Skip to main content
OpenTrials
Completed

NCT Number: NCT01172600

Effect of Nitrous Oxide in Treating Neuropathic Pain: A Study in Chronic Low Back Pain Patients

Epidural injection will be completed under fluoroscopy and all patients will receive 1-4 mg of Midazolam for relaxation before procedure and, if needed, 50-100 mcg of Fentanyl intravenous (IV). Radiopaque contrast (Omnipaque 300), for confirming the epidural position of the needle, steroids and local anesthetic agents will be used according to the physician performing the block and will not be controlled by the study. Patients will be randomly assigned to receive either inhaled Entonox along with the interventional block they are scheduled for or oxygen. They will be blinded about the treatment they are receiving. Those randomized to Entonox will inhale the gas through a mouthpiece throughout the procedure and also continue to receive it for a total of 4 hours in the recovery. Those randomized to the oxygen group will receive oxygen through a similar mouthpiece for the entire duration of the procedure and recovery for 4 hours. Following completion of procedure the patient will be transferred to recovery and monitored for 3-5 hours then discharged home with instructions. Possible side effects will be monitored and recorded, pain score of patient will be recorded before discharge. All the patients will receive standard instructions regarding physical back exercises. This will be repeated for every procedure up to maximum of three blocks.

The patients will be followed during each block and over a period of 1, 3, 6 and 12 months and on each follow-up visit will complete computerized set of questionnaires as they did before the procedure. The patients charts will be then reviewed for one year after the initial procedure to determine if further epidural steroid injections or surgery for the presenting problem were required. It is anticipated that the appropriate number of patients will be enrolled within six months of study initiation.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 to 80 years old at time of the first procedure
  • Male or female
  • History of chronic low back pain for longer than 6 months due to radiculopathy, symptomatic spinal canal stenosis, disc prolapse, postlaminectomy syndrome
  • magnetic resonance imaging or electromyographic evidence of nerve root damage
  • Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) score of >12
  • No or minimal evidence of facet joint pathology

Exclusion criteria

  • Known contraindications for epidural injection
  • Patients with ongoing workers' compensation claims
  • unstable or heavy opioid use (400 mg of morphine equivalents daily),
  • psychiatric disorders
  • medical illness, including conditions that could interfere with the interpretation of the outcome assessments
  • pregnant or lactating women
  • Current or recent drug abuse (within past 6 months).
  • Patient refuses regional analgesia.
  • Alcohol or drug abuse

Treatment and study plan

Entonox

Other

Those randomized to Entonox will inhale the gas through a mouthpiece throughout the procedure and also continue to receive it for a total of 4 hours in the recovery.

Other names: Nitrous Oxide

Oxygen

Other

Those randomized to oxygen will inhale it through a mouthpiece throughout the procedure and also continue to receive it for a total of 4 hours in the recovery.

Primary outcomes

  1. Change in VAS Pain Score From Baseline to 3 Month Follow-up

    Time frame: At baseline (before 1st block) and 3 months follow-up after last block (maximum of 3 blocks with a typical 1 month interval between blocks)

    10-cm-long Visual Analog Scale (VAS) pain score, ranges from 0 (no pain) to 10 (worst pain imaginable). It was measured before 1st 2nd and 3rd block and at 3 month follow-up.

    The primary outcome was the change in VAS pain score from baseline (before 1st block) to the 3 month follow-up.

  2. Change in VAS Pain Score From Baseline to Before 2nd Block

    Time frame: At baseline (before 1st block) and before the 2nd block, typically at 1 month from baseline

    10-cm-long Visual Analog Scale (VAS) pain score, ranges from 0 (no pain) to 10 (worst pain imaginable). It was measured before 1st 2nd and 3rd block and at 3 month follow-up.

    The primary outcome was the change in VAS pain score from baseline (before 1st block) to before the 2nd block.

  3. Change in VAS Pain Score From Baseline to Before 3rd Block

    Time frame: At baseline (before 1st block) and before the 3rd block, typically at 2 months from baseline

    10-cm-long Visual Analog Scale (VAS) pain score, ranges from 0 (no pain) to 10 (worst pain imaginable). It was measured before 1st 2nd and 3rd block and at 3 month follow-up.

    The primary outcome was the change in VAS pain score from baseline (before 1st block) to before the 3rd block

Secondary outcomes

  1. Change in Oswestry Score (% of Disability) From Baseline to 2nd Block

    Time frame: At baseline (before 1st block) and before the 2nd block, typically at 1 month from baseline

    Oswestry score ranges from 0% to 100%, which measures % of disability. The outcome is change in the Oswestry score from baseline (before 1st block) to before 2nd block.

  2. Change in Oswestry Score (% of Disability) From Baseline to 3rd Block

    Time frame: At baseline (before 1st block) and before the 3rd block, typically at 2 months from baseline

    Oswestry score ranges from 0% to 100%, which measures % of disability. The outcome is change in the Oswestry score from baseline (before 1st block) to before 3rd block.

  3. Change in Oswestry Score (% of Disability) From Baseline to 3 Months Follow-up

    Time frame: At baseline (before 1st block) and 3 months follow-up after last block (maximum of 3 blocks with a typical 1 month interval between blocks)

    Oswestry score ranges from 0% to 100%, which measures % of disability. The outcome is change in the Oswestry score from baseline (before 1st block) to 3 months follow-up.

  4. Usage of Opioids

    Time frame: 2nd block, typically at 1 month from baseline

  5. Usage of Opioid

    Time frame: 3rd block, typically at 2 months from baseline

  6. Usage of Opioid

    Time frame: 3 months follow-up after last block (maximum of 3 blocks with a typical 1 month interval between blocks)

  7. Biomarkers

    Time frame: baseline - before 1st block

    BIOMARKERS: IL-1β, IL-6, IL-10, 1L-17A, IFN-γ, and TNF-α

  8. Biomarkers

    Time frame: before 2nd block, typically at 1 month from baseline

    BIOMARKERS: IL-1β, IL-6, IL-10, 1L-17A, IFN-γ, and TNF-α

  9. Biomarkers

    Time frame: before 3rd block, typically at 2 months from baseline

    BIOMARKERS: IL-1β, IL-6, IL-10, 1L-17A, IFN-γ, and TNF-α

  10. Biomarkers

    Time frame: 3 months follow-up after last block (maximum of 3 blocks with a typical 1 month interval between blocks)

    BIOMARKERS: IL-1β, IL-6, IL-10, 1L-17A, IFN-γ, and TNF-α

Sponsors and collaborators

Lead sponsor

The Cleveland Clinic

Other

Registry information

Official study title

Effect of Nitrous Oxide in Treating Neuropathic Pain: A Pilot Study in Chronic Low Back Pain Patients

Important dates

Study start
2011
Primary completion
2013
Study completion
2013
First posted
Jul 30, 2010
Registry last updated
Oct 17, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.